Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* A female subject of childbearing potential who is sexually active using contraception.~* Subject is willing to abstain from all sexual contact involving her genitalia for at least 24 hours prior to and 24 hours after study drug administration.~* Subject must be neither pregnant nor lactating from Screening throughout the duration of the study.~* Subject has 1 of the following:~  * Menstruating with a stable cycle and has at least 21 non-bleeding days.~ * Amenorrheic (due to injectable or extended-cycle contraceptives).~* Subject is willing to refrain from using vaginal douche products during the treatment period and through the Follow-up Month 4 visit.~* Subject has a Pap test interpretation of either low-grade squamous intraepithelial lesions or atypical squamous cells of undetermined significance.~* Subject has a uterine cervical sample that is high-risk human papillomavirus positive.~Exclusion Criteria:~* The Subject has evidence of an uncontrolled, clinically significant medical condition as determined by the investigator.~* The Subject has a history of hemorrhagic diatheses or coagulopathy.~* The Subject has a history of toxic shock syndrome.~* The Subject has received any of the following medications in the timeframes listed below:~  * 851 (in any form) or an active (non-placebo) human papillomavirus vaccine at any time prior to the screening visit.~ * In the 4 weeks prior to the screening visit the subject has received:~    * Interferon therapy or other therapies that promote a proinflammatory immune state, including:~      * immunomodulators.~     * cytotoxic drugs.~     * drugs known to have major organ toxicity.~   * Used a vaginal douche 72 hours prior to the screening visit.~   * Received any investigational drug within 60 days of Study Day 1.~   * Used in the 2 weeks prior to Study Day 1:~      * oral or inhaled corticosteroids (\>1000 mcg/day, fluticasone propionate \>600 mg/day, or equivalent).~     * systemic steroids.~     * topical drugs to the anogenital area.~     * NuvaRing.~* The Subject has a history of hypersensitivity to any components of the gel formulation or to iodine.~* The Subject has given birth or has had a spontaneous or induced abortion within 2 months of Study Day 1.~* The Subject uses an intrauterine device, diaphragm, NuvaRing, or additional contraceptive foam or gel for birth control.~* The Subject has:~  * histology read as high-grade cervical intraepithelial neoplasia.~ * cytology read as high-grade squamous intraepithelial lesion.~ * cytology read as atypical glandular cytological abnormalities.~ * cytology read as atypical squamous cells - cannot exclude high grade.~ * cervical carcinoma of any type.~ * apparent endocervical involvement.~ * high-grade vulvar intraepithelial neoplasia.~ * high-grade vaginal intraepithelial neoplasia.~* If the limits of a cervical lesion cannot be readily visualized.~* If the limits of the transformation zone cannot be readily visualized.~* The subject has clinical evidence of a vaginal infection or sexually transmitted infection, other than cervical human papillomavirus infection at the Study Day 1 visit.~* The Subject has had a cervical biopsy within 1 month prior to the screening visit.~* The Subject has had any previous ablative or surgical treatment of the cervix within 3 months prior to the screening visit;~* The Subject has a history of alcoholism or substance abuse within 1 year or has current alcohol or substance abuse as assessed by the investigator.~* The Subject has tested positive for human immunodeficiency virus at the screening visit or has evidence of any other immunosuppressive disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None
- 6 (Type: EXPERIMENTAL): None
- 7 (Type: EXPERIMENTAL): None
- 8 (Type: PLACEBO_COMPARATOR): None
- 9 (Type: PLACEBO_COMPARATOR): None
- 10 (Type: PLACEBO_COMPARATOR): None
- 11 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).